Sickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ Pharma Companies Rigorously Developing Drugs for the Market Entry

Key Takeaways from the Sickle Cell Disease Competitive Landscape Report Key Takeaways from the Sickle Cell Disease Competitive Landscape Report Request a sample and discover the recent advances in sickle cell disease treatment drugs @Sickle Cell Disease Competitive Landscape Report Sickle Cell Disease Overview Sickle cell disease is a group of inherited red blood cell diseases that affect hemoglobin, the protein that transports oxygen throughout the body. Red blood cells in...

Key Takeaways from the Sickle Cell Disease Competitive Landscape Report

Request a sample and discover the recent advances in sickle cell disease treatment drugs @ Sickle Cell Disease Competitive Landscape Report

Sickle Cell Disease Overview

Sickle cell disease is a group of inherited red blood cell diseases that affect hemoglobin, the protein that transports oxygen throughout the body. Red blood cells in good health are spherical and flow through small blood channels to carry oxygen to all regions of the body. Sickle cell disease patients have defective hemoglobin, which causes red blood cells to become hard and sticky, resembling a C-shaped farm tool known as a "sickle." Sickle cell disease can be prevented during pregnancy, diagnosed in utero or during the newborn period, or found at any time during life. The sort of tests performed is determined by the patient's age. DNA testing can be utilized for prenatal diagnosis or to validate a sickle cell genotype diagnosis. Neonate screening is offered in the majority of US states and involves hemoglobin electrophoresis.

The goal of sickle cell anemia treatment is usually to avoid crises, relieve symptoms, and prevent consequences. Some medical treatments and home cures are available to help you feel better. Medication to relieve discomfort and prevent complications, blood transfusions, and a bone marrow transplant are all possible treatments. Researchers are investigating if putting a normal gene into the bone marrow of persons with sickle cell anemia can result in normal hemoglobin, as well as turning off the defective gene while reactivating another gene important for fetal hemoglobin production.

Find out more about sickle cell disease treatment drugs @ Drugs for Sickle Cell Disease Treatment

Sickle Cell Disease Pipeline Analysis: Drug Profile

Inclacumab: Pfizer

Inclacumab is a completely human IgG4 anti-P-selectin monoclonal antibody that is being developed to reduce vaso-occlusive crises (VOCs) in sickle cell disease patients. P-selectin is a protein that mediates cell adhesion and has been scientifically proven to alleviate discomfort caused by VOCs in persons with sickle cell disease. Preclinical data indicate that inclacumab has the potential to be a best-in-class alternative for lowering VOCs in persons with sickle cell disease, with quarterly rather than monthly treatment. Global Blood Therapeutics (GBT), which was acquired by Pfizer, created the medication. As part of its licensing arrangement with Roche, GBT owns exclusive worldwide rights to inclacumab. Inclacumab is currently in Phase III development for sickle cell disease.

Mitapivat: Agios Pharmaceuticals

Mitapivat is an orally administered small drug that activates the enzyme pyruvate kinase-R (PKR). This enzyme is required for glycolysis, which is the process of producing cellular energy by breaking down sugar molecules. When the PKR enzyme is activated, it consumes 2, 3-diphosphoglycerate (2, 3-DPG). In SCD, it is assumed that 2, 3-DPG accumulates in red blood cells, causing them to become malformed by causing hemoglobin molecules to clump together in a process known as polymerization. Mitapivatis is intended to reduce 2, 3-DPG accumulation and thereby hemoglobin polymerization and red blood cell sickling via activating PKR. Agios Pharmaceuticals has launched the RISE UP Phase II/III trial to evaluate the experimental treatment Mitapivat (AG-348) in people with sickle cell disease.

A snapshot of the Sickle Cell Disease Pipeline Drugs mentioned in the report:

 

Learn more about the emerging sickle cell disease pipeline therapies @ Sickle Cell Disease Clinical Trials

Scope of the Sickle Cell Disease Competitive Landscape Report 

Dive deep into rich insights for new drugs for sickle cell disease treatment, visit @ Sickle Cell Disease Drugs

Table of Contents

 

For further information on the sickle cell disease pipeline therapeutics, reach out @ Sickle Cell Disease Treatment Drugs

Related Reports

Sickle Cell Disease Market

Sickle Cell Disease Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Sickle Cell Disease companies, including Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics, Takeda, among others.

Sickle Cell Disease Epidemiology

Sickle Cell Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Sickle Cell Disease epidemiology in the 7MM.

Beta Thalassemia Market

Beta Thalassemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key beta thalassemia companies, including Novartis, Merck, Bristol Myers Squibb, Chiesi Farmaceutici S.p.A, Bluebird Bio, among others.

Thalassemia Market

Thalassemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thalassemia companies, including Forma therapeutics, Ionis Pharmaceuticals, Gamida-Cell, Silence Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Contact Us

Shruti Thakur
info@delveinsight.com
+1(919)321-6187 
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/sickle-cell-disease-clinical-trial-pipeline-accelerates-as-40-pharma-companies-rigorously-developing-drugs-for-the-market-entry-301873929.html